Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 16684
Country/Region: Kenya
Year: 2018
Main Partner: Elizabeth Glaser Pediatric AIDS Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $522,485 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $9,975
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $50,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $107,392
Sexual Prevention: Other Sexual Prevention (HVOP) $130,060
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $9,940
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $200,156
Treatment: Pediatric Treatment (PDTX) $14,962
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 343
HTS_SELF 15-19, Female, Directly-Assisted 2019 17
HTS_SELF 15-19, Female, Unassisted 2019 17
HTS_SELF 15-19, Male, Directly-Assisted 2019 4
HTS_SELF 15-19, Male, Unassisted 2019 4
HTS_SELF 20-24, Female, Directly-Assisted 2019 17
HTS_SELF 20-24, Female, Unassisted 2019 17
HTS_SELF 20-24, Male, Directly-Assisted 2019 4
HTS_SELF 20-24, Male, Unassisted 2019 4
HTS_SELF 25-29, Female, Directly-Assisted 2019 17
HTS_SELF 25-29, Female, Unassisted 2019 17
HTS_SELF 25-29, Male, Directly-Assisted 2019 4
HTS_SELF 25-29, Male, Unassisted 2019 4
HTS_SELF 30-34, Female, Directly-Assisted 2019 17
HTS_SELF 30-34, Female, Unassisted 2019 17
HTS_SELF 30-34, Male, Directly-Assisted 2019 4
HTS_SELF 30-34, Male, Unassisted 2019 4
HTS_SELF 35-39, Female, Directly-Assisted 2019 17
HTS_SELF 35-39, Female, Unassisted 2019 17
HTS_SELF 35-39, Male, Directly-Assisted 2019 4
HTS_SELF 35-39, Male, Unassisted 2019 4
HTS_SELF 40-49, Female, Directly-Assisted 2019 17
HTS_SELF 40-49, Female, Unassisted 2019 17
HTS_SELF 40-49, Male, Directly-Assisted 2019 4
HTS_SELF 40-49, Male, Unassisted 2019 4
HTS_SELF 50+, Female, Directly-Assisted 2019 17
HTS_SELF 50+, Female, Unassisted 2019 17
HTS_SELF 50+, Male, Directly-Assisted 2019 4
HTS_SELF 50+, Male, Unassisted 2019 4
HTS_SELF Directly-Assisted 2019 172
HTS_SELF FSW, Directly-Assisted 2019 228
HTS_SELF Unassisted 2019 171
HTS_SELF Unassisted - Other 2019 16
HTS_SELF Unassisted - Self 2019 86
HTS_SELF Unassisted - Sex Partner 2019 68
HTS_TST 15-19, Female, Negative 2019 50
HTS_TST 15-19, Male, Negative 2019 27
HTS_TST 20-24, Female, Negative 2019 186
HTS_TST 20-24, Male, Negative 2019 100
HTS_TST 25-29, Female, Negative 2019 1,892
HTS_TST 25-29, Female, Negative 2019 885
HTS_TST 25-29, Female, Negative 2019 63
HTS_TST 25-29, Female, Negative 2019 7
HTS_TST 25-29, Female, Negative 2019 1,291
HTS_TST 25-29, Male, Negative 2019 1,758
HTS_TST 25-29, Male, Negative 2019 19
HTS_TST 25-29, Male, Negative 2019 9
HTS_TST 25-29, Male, Negative 2019 816
HTS_TST 30-34, Female, Negative 2019 2,115
HTS_TST 30-34, Female, Negative 2019 885
HTS_TST 30-34, Female, Negative 2019 76
HTS_TST 30-34, Female, Negative 2019 6
HTS_TST 30-34, Female, Negative 2019 1,476
HTS_TST 30-34, Male, Negative 2019 2,110
HTS_TST 30-34, Male, Negative 2019 24
HTS_TST 30-34, Male, Negative 2019 12
HTS_TST 30-34, Male, Negative 2019 982
HTS_TST 35-39, Female, Negative 2019 747
HTS_TST 35-39, Female, Negative 2019 885
HTS_TST 35-39, Female, Negative 2019 18
HTS_TST 35-39, Female, Negative 2019 7
HTS_TST 35-39, Female, Negative 2019 368
HTS_TST 35-39, Male, Negative 2019 1,238
HTS_TST 35-39, Male, Negative 2019 24
HTS_TST 35-39, Male, Negative 2019 17
HTS_TST 35-39, Male, Negative 2019 982
HTS_TST 40-49, Female, Negative 2019 747
HTS_TST 40-49, Female, Negative 2019 885
HTS_TST 40-49, Female, Negative 2019 18
HTS_TST 40-49, Female, Negative 2019 6
HTS_TST 40-49, Female, Negative 2019 368
HTS_TST 40-49, Male, Negative 2019 411
HTS_TST 40-49, Male, Negative 2019 7
HTS_TST 40-49, Male, Negative 2019 17
HTS_TST 40-49, Male, Negative 2019 326
HTS_TST 50+, Female, Negative 2019 8
HTS_TST 50+, Male, Negative 2019 3
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 66,127
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 8
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 775
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 2,319
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 6
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,738
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 642
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 500
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1,829
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 2,252
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 8,827
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 4,855
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 376
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 206
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 4
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 7
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 7
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 9
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 10
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 6
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 8
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 6
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 15
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 2,352
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 1,734
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 8,097
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 5,541
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 183
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 164
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 474
HTS_TST_POS 25-29, Female, Positive 2019 53
HTS_TST_POS 25-29, Female, Positive 2019 79
HTS_TST_POS 25-29, Female, Positive 2019 1
HTS_TST_POS 25-29, Female, Positive 2019 9
HTS_TST_POS 25-29, Male, Positive 2019 51
HTS_TST_POS 25-29, Male, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 8
HTS_TST_POS 30-34, Female, Positive 2019 58
HTS_TST_POS 30-34, Female, Positive 2019 13
HTS_TST_POS 30-34, Female, Positive 2019 1
HTS_TST_POS 30-34, Female, Positive 2019 12
HTS_TST_POS 30-34, Male, Positive 2019 62
HTS_TST_POS 30-34, Male, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 9
HTS_TST_POS 35-39, Female, Positive 2019 18
HTS_TST_POS 35-39, Female, Positive 2019 11
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 39
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 9
HTS_TST_POS 40-49, Female, Positive 2019 18
HTS_TST_POS 40-49, Female, Positive 2019 6
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 11
HTS_TST_POS 40-49, Male, Positive 2019 3
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 52
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 29
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 61
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 62
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 283
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 133
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 71
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 46
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 1
PMTCT_ART Already on ART at beginning of current pregnancy 2019 175
PMTCT_ART New on ART 2019 164
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 339
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 6,780
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 42
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 42
PMTCT_EID Sum of Infant Age disaggregates 2019 42
PMTCT_STAT 25-29, Female 2019 911
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 32
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 852
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 22
PMTCT_STAT 30-34, Female 2019 920
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 32
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 864
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 22
PMTCT_STAT 35-39, Female 2019 902
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 32
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 843
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 22
PMTCT_STAT 40-49, Female 2019 900
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 32
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 845
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 22
PMTCT_STAT By Age (Numerator): 10-14 2019 11
PMTCT_STAT By Age (Numerator): 15-19 2019 781
PMTCT_STAT By Age (Numerator): 20-24 2019 2,349
PMTCT_STAT By Age (Numerator): 50+ 2019 6
PMTCT_STAT By Number of known positives: 15-19 2019 7
PMTCT_STAT By Number of known positives: 20-24 2019 46
PMTCT_STAT By Number of new negative: 10-14 2019 10
PMTCT_STAT By Number of new negative: 15-19 2019 756
PMTCT_STAT By Number of new negative: 20-24 2019 2,252
PMTCT_STAT By Number of new negative: 50+ 2019 5
PMTCT_STAT By Number of new positives: 15-19 2019 22
PMTCT_STAT By Number of new positives: 20-24 2019 62
PMTCT_STAT Number of new ANC and L&D clients 2019 6,874
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 6,780
PMTCT_STAT_den 25-29, Female 2019 923
PMTCT_STAT_den 30-34, Female 2019 920
PMTCT_STAT_den 35-39, Female 2019 921
PMTCT_STAT_den 40-49, Female 2019 923
PMTCT_STAT_den By Age (Denominator): <15-19 2019 808
PMTCT_STAT_den By Age (Denominator): 10-14 2019 10
PMTCT_STAT_den By Age (Denominator): 20-24 2019 2,357
PMTCT_STAT_den By Age (Denominator): 50+ 2019 12
PP_PREV 25-29, Female 2019 974
PP_PREV 25-29, Male 2019 1,088
PP_PREV 30-34, Female 2019 974
PP_PREV 30-34, Male 2019 1,088
PP_PREV 35-39, Female 2019 974
PP_PREV 35-39, Male 2019 1,088
PP_PREV 40-49, Female 2019 974
PP_PREV 40-49, Male 2019 1,088
PP_PREV Age/sex: 10-14 Female 2019 4,357
PP_PREV Age/sex: 10-14 Male 2019 374
PP_PREV Age/sex: 15-19 Female 2019 11,078
PP_PREV Age/sex: 15-19 Male 2019 2,674
PP_PREV Age/sex: 20-24 Female 2019 9,517
PP_PREV Age/sex: 20-24 Male 2019 1,757
PP_PREV Age/sex: 50+ Female 2019 251
PP_PREV Age/sex: 50+ Male 2019 379
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 38,635
PP_PREV Sum of Age/Sex disaggregates 2019 30,387
PrEP_NEW 25-29, Female 2019 17
PrEP_NEW 25-29, Male 2019 3
PrEP_NEW 30-34, Female 2019 6
PrEP_NEW 30-34, Male 2019 8
PrEP_NEW 35-39, Female 2019 7
PrEP_NEW 35-39, Male 2019 5
PrEP_NEW 40-49, Female 2019 6
PrEP_NEW 40-49, Male 2019 2
PrEP_NEW Female 15-19 2019 16
PrEP_NEW Female 20-24 2019 59
PrEP_NEW Female 50+ 2019 2
PrEP_NEW Male 20-24 2019 11
PrEP_NEW Male 50+ 2019 1
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 143
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 21
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 30
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 51
TB_PREV By Age/Sex (Numerator): <15, Female 2019 59
TB_PREV By Age/Sex (Numerator): <15, Male 2019 144
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 806
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 318
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 1,327
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 1,372
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 61
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 148
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 834
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 329
TB_PREV_den IPT, Life-long ART, New, Positive 2019 793
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 8
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 98
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 8
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 136
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 250
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 253
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 8
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 100
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 8
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 137
TX_CURR 25-29, Female, Positive 2019 638
TX_CURR 25-29, Male, Positive 2019 171
TX_CURR 30-34, Female, Positive 2019 490
TX_CURR 30-34, Male, Positive 2019 276
TX_CURR 35-39, Female, Positive 2019 481
TX_CURR 35-39, Male, Positive 2019 267
TX_CURR 40-49, Female, Positive 2019 331
TX_CURR 40-49, Male, Positive 2019 267
TX_CURR Age/Sex: <1 2019 2
TX_CURR Age/Sex: <1-9 2019 93
TX_CURR Age/Sex: 10-14 Female 2019 58
TX_CURR Age/Sex: 10-14 Male 2019 54
TX_CURR Age/Sex: 15-19 Female 2019 129
TX_CURR Age/Sex: 15-19 Male 2019 77
TX_CURR Age/Sex: 20-24 Female 2019 360
TX_CURR Age/Sex: 20-24 Male 2019 103
TX_CURR Age/Sex: 50+ Female 2019 265
TX_CURR Age/Sex: 50+ Male 2019 95
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 4,157
TX_CURR Sum of age/sex disaggregates 2019 206
TX_NEW 25-29, Female, Positive 2019 60
TX_NEW 25-29, Male, Positive 2019 55
TX_NEW 30-34, Female, Positive 2019 81
TX_NEW 30-34, Male, Positive 2019 60
TX_NEW 35-39, Female, Positive 2019 26
TX_NEW 35-39, Male, Positive 2019 53
TX_NEW 40-49, Female, Positive 2019 14
TX_NEW 40-49, Male, Positive 2019 18
TX_NEW Breastfeeding status 2019 18
TX_NEW By Age/Sex: <1 2019 7
TX_NEW By Age/Sex: 1-9 2019 14
TX_NEW By Age/Sex: 10-14 Female 2019 7
TX_NEW By Age/Sex: 10-14 Male 2019 5
TX_NEW By Age/Sex: 15-19 Female 2019 94
TX_NEW By Age/Sex: 15-19 Male 2019 54
TX_NEW By Age/Sex: 20-24 Female 2019 313
TX_NEW By Age/Sex: 20-24 Male 2019 220
TX_NEW By Age/Sex: 50+ Female 2019 8
TX_NEW By Age/Sex: 50+ Male 2019 6
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 1,095
TX_NEW Pregnancy status 2019 94
TX_NEW Sum of Age/Sex disaggregates 2019 707
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 3,105
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 86
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 2
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 75
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 1
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 1,912
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 98
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 886
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 45
TX_PVLS_den Denominator: Indication: Routine 2019 2,959
TX_PVLS_den Denominator: Indication: Targeted 2019 146
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 37
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 20
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 979
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 487
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 1,523
TX_RET Numerator by Status: Breastfeeding 2019 27
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 1,574
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 37
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 20
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,013
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 504
TX_RET_den Denominator by Status: Breastfeeding 2019 25
TX_RET_den Denominator by Status: Pregnant 2019 97
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 3,984
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 150
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 164
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 2,398
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 1,272
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 183
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 33
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 225
Cross Cutting Budget Categories and Known Amounts Total: $25,000
Renovation $25,000